甲状腺癌与 COVID-19：治疗方法和药物研发的前景。
Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development.
机构信息
Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, China.
出版信息
Front Endocrinol (Lausanne). 2022 May 4;13:873027. doi: 10.3389/fendo.2022.873027. eCollection 2022.
Thyroid cancer is the most prevalent endocrine malignancy and the reported incidence of thyroid cancer has continued to increase in recent years. Since 2019, coronavirus disease 2019 (COVID-19) has been spreading worldwide in a global pandemic. COVID-19 aggravates primary illnesses and affects disease management; relevant changes include delayed diagnosis and treatment. The thyroid is an endocrine organ that is susceptible to autoimmune attack; thus, thyroid cancer after COVID-19 has gradually attracted attention. Whether COVID-19 affects the diagnosis and treatment of thyroid cancer has also attracted the attention of many researchers. This review examines the literature regarding the influence of COVID-19 on the pathogenesis, diagnosis, and treatment of thyroid cancer; it also focuses on drug therapies to promote research into strategies for improving therapy and management in thyroid cancer patients with COVID-19.
甲状腺癌是最常见的内分泌恶性肿瘤，近年来甲状腺癌的报告发病率持续上升。自 2019 年以来，2019 冠状病毒病（COVID-19）在全球范围内大流行。COVID-19 可加重原发性疾病并影响疾病管理；相关变化包括诊断和治疗的延迟。甲状腺是内分泌器官，易受到自身免疫攻击；因此，COVID-19 后的甲状腺癌逐渐受到关注。COVID-19 是否影响甲状腺癌的诊断和治疗也引起了许多研究人员的关注。本综述探讨了 COVID-19 对甲状腺癌发病机制、诊断和治疗的影响；还重点关注药物治疗，以促进研究制定策略，改善 COVID-19 甲状腺癌患者的治疗和管理。
Zotero 插件